ARE

Alexandria Real Estate Equities

Stock NYSE – Stock Market Prices, News & Analysis

Alexandria Real Estate Equities Inc is specialized in real estate for life sciences companies. It owns, manages, develops, and acquires specialized properties in the biotechnology and pharmaceutical sectors.

$ 43.12

1.04 %

United States REIT—Office US0152711091

Alexandria Real Estate Equities

$ 43.12

1.04 %

ARE

biotechnology pharmaceutical specialized-real-estate

United States REIT—Office US0152711091

Price history of Alexandria Real Estate Equities

Performance & Momentum

6 Months 46.89 %

1 Year 50.19 %

3 Years 59.40 %

5 Years 68.24 %

Momentum

Unlock this indicator

Alexandria Real Estate Equities Declares $0.72 Quarterly Dividend

Strategic Analysis

Alexandria Real Estate Equities • 2026

Alexandria Real Estate Equities Inc positions itself as a niche player in specialized real estate, primarily serving the biotechnology and pharmaceutical sectors in the United States. Its business model relies on the ownership and management of properties highly tailored to the specific needs of life sciences, creating a barrier to entry that is difficult to replicate.

Strengths

Strong specialization in a rapidly growing real estate segment related to biotechnology
Real estate portfolio adapted to the technical requirements of scientific tenants
Strategic geographical positioning with assets located in key research hubs

Weaknesses

Vulnerability to cyclicality and financial pressures specific to the biotech and pharma sector
Deteriorated stock performance with a prolonged downward trend reflecting structural challenges

Momentum

The current momentum is unfavorable, characterized by a sustained downward trend over several years, highlighting difficulties in adaptation or perception among investors. This situation calls for caution and requires careful monitoring of developments in the biotech sector and Alexandria's ability to maintain its rental attractiveness.

Analysis performed 1 month ago